More and more anxiety and depression after colorectal cancer are related to these factors

Share This Post

In a study published online on April 6 in Cancer, the prevalence of depression and anxiety increased among patients with colorectal cancer (CRC).

The team of Dr. Floortje Mols from the University of Tilburg in the Netherlands examined the symptoms of depression and anxiety in patients with CRC. Between 2000 and 2013, 2,625 patients diagnosed with CRC completed the Hospital Anxiety and Depression Scale and the European Cancer Quality of Life Questionnaire, which included a sample of 315 individuals with age and gender matching specifications.

The researchers found that patients reported significantly higher prevalence of depression (19% vs 12.8%) and anxiety disorder (20.9% vs 11.8%) compared to the standard sample. The longer the diagnosis of cancer, the more the depression symptoms are reduced; the older men are less likely to be anxious, but they are more prone to depression; the married patients’ anxiety and depression are reduced; the lower the education level, the more comorbid diseases, the more anxiety and depression. Severe anxiety and depression symptoms are associated with lower global quality of life, physical condition, role, cognition, mood, and social function.

Therefore, screening and referral are the most important, especially for those who are single, have low education, and have many comorbidities.


For details on colorectal cancer treatment and second opinion, do call us at +91 96 1588 1588 or write to

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form